Pub Date : 2021-11-01DOI: 10.1007/s40274-021-08195-6
{"title":"UK's NICE does not recommend tucatinib for HER2-positive metastatic breast cancer","authors":"","doi":"10.1007/s40274-021-08195-6","DOIUrl":"https://doi.org/10.1007/s40274-021-08195-6","url":null,"abstract":"","PeriodicalId":19781,"journal":{"name":"PharmacoEconomics & Outcomes News","volume":"58 14","pages":"37"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91448841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-01DOI: 10.1007/s40274-021-08180-7
{"title":"Prescription digital therapeutic, reSET-O, saves costs in US patients with opioid use disorder","authors":"","doi":"10.1007/s40274-021-08180-7","DOIUrl":"https://doi.org/10.1007/s40274-021-08180-7","url":null,"abstract":"","PeriodicalId":19781,"journal":{"name":"PharmacoEconomics & Outcomes News","volume":"8 1","pages":"22 - 22"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86708579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-01DOI: 10.1007/s40274-021-08200-0
{"title":"Breast reduction surgery for symptomatic breast hypertrophy cost effective in Australia","authors":"","doi":"10.1007/s40274-021-08200-0","DOIUrl":"https://doi.org/10.1007/s40274-021-08200-0","url":null,"abstract":"","PeriodicalId":19781,"journal":{"name":"PharmacoEconomics & Outcomes News","volume":"5 1","pages":"5 - 5"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73099361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-01DOI: 10.1007/s40274-021-08194-6
{"title":"Scottish Medicines Consortium accepts three new medicines and rejects one","authors":"","doi":"10.1007/s40274-021-08194-6","DOIUrl":"https://doi.org/10.1007/s40274-021-08194-6","url":null,"abstract":"","PeriodicalId":19781,"journal":{"name":"PharmacoEconomics & Outcomes News","volume":"82 1","pages":"36"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90100408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-01DOI: 10.1007/s40274-021-08209-0
{"title":"Discontinuing antidepressants: no QALY gain, no cost savings in the short term in the UK","authors":"","doi":"10.1007/s40274-021-08209-0","DOIUrl":"https://doi.org/10.1007/s40274-021-08209-0","url":null,"abstract":"","PeriodicalId":19781,"journal":{"name":"PharmacoEconomics & Outcomes News","volume":"61 1","pages":"14 - 14"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76501955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-01DOI: 10.1007/s40274-021-08169-9
{"title":"Empagliflozin less costly than other branded AHAs for T2DM patients with CVD in the USA","authors":"","doi":"10.1007/s40274-021-08169-9","DOIUrl":"https://doi.org/10.1007/s40274-021-08169-9","url":null,"abstract":"","PeriodicalId":19781,"journal":{"name":"PharmacoEconomics & Outcomes News","volume":"1 1","pages":"11 - 11"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88755882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-01DOI: 10.1007/s40274-021-08217-z
{"title":"Similar costs for mCRPC patients treated with abiraterone vs enzalutamide in Scotland","authors":"","doi":"10.1007/s40274-021-08217-z","DOIUrl":"https://doi.org/10.1007/s40274-021-08217-z","url":null,"abstract":"","PeriodicalId":19781,"journal":{"name":"PharmacoEconomics & Outcomes News","volume":"46 1","pages":"22 - 22"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88994309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：